Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. - Wikidata - awgldk - TriplyDB

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

http://www.wikidata.org/entity/Q39926383

about

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth mTOR inhibitors in advanced renal cell carcinoma State of the science: an update on renal cell carcinoma Hypoxia-Inducible Factors (HIFs) and Phosphorylation: Impact on Stability, Localization, and Transactivity Oncogenes strike a balance between cellular growth and homeostasis The PI3K/AKT Pathway and Renal Cell Carcinoma Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma Diverse mechanisms of AKT pathway activation in human malignancy HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway flux The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy The influence of rapamycin on the early cardioprotective effect of hypoxic preconditioning on cardiomyocytes The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.Chronic opioids regulate KATP channel subunit Kir6.2 and carbonic anhydrase I and II expression in rat adrenal chromaffin cells via HIF-2α and protein kinase A Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.The genetic basis of kidney cancer: a metabolic disease Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2 Regulation of Akt during torpor in the hibernating ground squirrel, Ictidomys tridecemlineatus.mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.Everolimus - a new approach in the treatment of renal cell carcinoma Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.Stratification of clear cell renal cell carcinoma by signaling pathway analysis.FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation.Future directions in renal cell carcinoma: 2011 and beyond Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer

P2860

Q24603549-3BEAB491-8402-44EB-BF01-A3548EDA1CC6 Q24612127-9B9A19C2-9AFE-40B3-803B-4634BDF7D89A Q24630685-02876273-A22D-4899-A8A5-D61DE7633318 Q26768230-BCF7D384-24D8-4407-9F47-8C47FB3E5CE7 Q26798085-5662E520-B439-4C83-B685-CFBE1350602C Q26800216-75E87770-18F9-4EAA-90F8-B7DCA30FCE57 Q26829730-1521554C-25FC-4F5C-AC4B-1A92E19FB4B8 Q26851604-87B1FF9B-5268-4340-B015-29E53E98BB19 Q27025886-630733D8-8A4E-414A-A4AB-F724B250BEFD Q27852466-E9140158-53FB-4EA5-A4E9-28A282BE8786 Q28079861-F5B0EB3B-3DDF-4EDB-AE89-BEE2E09FD28E Q28081442-2CA6D1C3-6618-4A57-8351-A61C10CA0A89 Q28478577-2E2D3B37-FD62-464C-9B89-1CDFBD038B2A Q28485220-BC92247D-F9A1-4D8C-9858-26726B2913CF Q28542639-483C3B49-DA50-4CA8-A6B0-08C3DDD6BB18 Q28765488-5100F547-00DC-4A41-8A23-E8FF9F0C12B4 Q29040166-142D52AE-F836-4406-AC61-EDD02D3766BD Q30425815-1943FEF7-DA7C-4A50-AFC1-86D8CA6632F4 Q33560677-19A5D000-EE86-4D0A-AE30-D2AFD72A16DC Q33655472-6991A579-9DF9-4F72-A54A-1398FFE5677A Q33728258-433792E6-91A3-4FFF-8B00-451FA0E1C14A Q33730033-4767CD1D-F1C1-4773-87BD-7DD925FFFAE6 Q33897336-BEB7A5B1-4874-488C-8BAE-5C2E4F1DA415 Q34001234-BE029A8D-E8AB-4957-B16E-E0CA6C237BA6 Q34001389-1223292F-DDC2-4C7F-8F89-EBB356D6A783 Q34077263-DC234A2D-F856-4C94-9A42-6F250159B363 Q34087148-5BF1FC96-A376-49F9-B31D-1DDABE4B2123 Q34102029-5296C0B6-6FCA-4474-94AB-EC10255E302C Q34107535-A55C2446-EA5D-4165-BF6E-749B3B56D1D8 Q34214012-91DD900B-9CD0-4BD0-A7E3-71929BA62E22 Q34394233-4A113103-4886-4540-8662-BE4181645583 Q34417931-7265B62C-ACA9-47A0-903D-8EE6F23EB751 Q34440440-02CFD04C-3FA7-4F4F-8DAB-D109C1D8616D Q34627828-205A1634-AD56-4052-B599-5F1513667F49 Q34995745-A66DAD6D-9EF8-4B8C-A737-FE5A2209F2FB Q35003274-AAF8D9E9-ADB0-4A9B-AB3A-CD0A70E29395 Q35103884-C8DF79DE-33EF-459D-8EF6-3D0A6AE7E76A Q35111461-A58350FF-06C6-4639-9D1F-EACDFB4A2AB6 Q35152107-80210753-FD31-4D6E-8613-D0CD8E4445E4 Q35169825-5B15CD53-99D1-4621-9E7A-0797E79883F8

P2860

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

http://www.wikidata.org/entity/Q39926383

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@en

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@nl

type

label

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@en

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@nl

prefLabel

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@en

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@nl

P1433

Q39926383-CAE7CEC4-7EEC-419C-9BCA-AC262C593CCB

P1476

Q39926383-EE17428A-DF02-432A-97F4-EF9053F9A496

P2093

Q39926383-1A4F0AA5-B154-4210-8DA5-A0D5B61F9F35

Q39926383-239F6D2E-77C2-4990-A97C-FB81B450B64D

Q39926383-6F33390E-A945-4966-9AC6-69F123BF51F3

Q39926383-ADEEEFA5-E3F0-4999-AB89-433390BC170D

Q39926383-B298BC77-F930-4987-8AFF-6E48E9C414E1

P2860

Q39926383-01879C41-B2F3-4A73-8312-5AECCC524A44

Q39926383-0C3F981A-55B6-4A34-9865-A35B75613C16

Q39926383-106D284B-2F3A-42C2-BEC7-F4596FAF7B21

Q39926383-157130BC-3113-41D0-BA07-205082E94DFB

Q39926383-17504C03-7133-4850-B789-5DD5A55E3A2F

Q39926383-2039933B-783F-486A-B884-3046ECF2D212

Q39926383-2B037110-C773-44EF-AE0D-FEB6BBF679A8

Q39926383-37B1CCD0-2DFF-4918-A4A9-21347311FAC0

Q39926383-40C59511-A1BD-4DAB-8A63-2E16F1C52B97

Q39926383-4B962735-57BD-495F-9A4A-FAC0E9FC22E7

P304

Q39926383-71936FBE-FB0F-4F84-9AA6-805329601980

P31

Q39926383-98D1FCFF-1646-4DEE-854F-5F535E013259

P356

Q39926383-89DC9ABC-5BFE-494C-BC82-BA9E4AD9843E

P407

Q39926383-BC773BF0-79CA-43A8-B0C3-7A307AF148CC

P433

Q39926383-BBA9736D-A9B9-45A7-9037-DC01407064A2

P478

Q39926383-185FDF77-719E-442C-9623-D19DD75DDF86

P577

Q39926383-2A59EFAB-A72D-4F98-B076-2AD5451DF78D

P698

Q39926383-5E45587D-0EE4-4FF4-A317-5EB709A1674D

P921

Q39926383-D6324337-3B90-4FA1-B248-CB2E158E208C

P932

Q39926383-558B95E4-3F9B-4C3D-8455-FAA16C7671B7

P356

P1433

Journal of Biological Chemistry

P1476

Differential dependence of hyp ...... 2 alpha on mTORC1 and mTORC2.

@en

P2093

Alfredo Toschi

http://www.w3.org/2001/XMLSchema#string

David A Foster

http://www.w3.org/2001/XMLSchema#string

Evan Lee

http://www.w3.org/2001/XMLSchema#string

Michael Ohh

http://www.w3.org/2001/XMLSchema#string

Noga Gadir

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

Mechanism of activation of protein kinase B by insulin and IGF-1

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

AKT/PKB signaling: navigating downstream

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

Defining the role of mTOR in cancer

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

P304

34495-34499

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.C800170200

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

283

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18945681

http://www.w3.org/2001/XMLSchema#string

P921

P932

2596400

http://www.w3.org/2001/XMLSchema#string